Advertisement

Drugs

, Volume 19, Issue 3, pp 195–219 | Cite as

Benzodiazepines: Clinical Pharmacology and Therapeutic Use

  • C. Bellantuono
  • V. Reggi
  • G. Tognoni
  • S. Garattini
Review Article

Keywords

Clinical Pharmacology Oxazepam Nitrazepam Clobazam Temazepam 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Achong, M.R.; Bayne, J.R.; Gerson, L.W. and Golshani, S.: Prescribing of psychoactive drugs for chronically ill elderly patients. Canadian Medical Association Journal 118: 1503–1508 (1978).PubMedGoogle Scholar
  2. Allen, M.D. and Greenblatt, D.J.: Hypnotics and sedatives; in Dukes (Ed) Side Effects of Drugs, Annual 3, pp.29–38 (Excerpta Medica, Amsterdam 1979).Google Scholar
  3. Alvan, G. and Odar-Cederlof, I.: The pharmacokinetic profile of oxazepam. Acta Psychiatrica Scandinavica (Supplementum) 274: 47–55 (1978).Google Scholar
  4. Annegers, J.F.; Hauser, W.A.; Elveback, L.R. and Kurland, L.T.: The risk of epilepsy following febrile convulsions. Neurology 29: 297–303 (1979).PubMedGoogle Scholar
  5. Athinarayanan, P.; Pierog, S.H.; Nigam, S.K. and Glass, L.: Chlordiazepoxide withdrawal in the neonate. American Journal of Obstetrics and Gynecology 124: 212–213 (1976).PubMedGoogle Scholar
  6. Balter, M.B.; Levine, J. and Manheimer, D.I.: Cross-national study of the extent of anti-anxiety/sedative drug use. New England Journal of Medicine 290: 769–774 (1974).PubMedGoogle Scholar
  7. Bergman, U.; Dahlstrom, M.; Gunnarsonn, C. and Westerholm, B.: Why are psychotropic drugs prescribed to out-patients? A methodological study. European Journal of Clinical Pharmacology 15: 249–256 (1979).PubMedGoogle Scholar
  8. Bielski, R.J. and Friedel, R.O.: Prediction of tricyclic antidepressant response. A critical review. Archives of General Psychiatry 33: 1479–1489 (1976).PubMedGoogle Scholar
  9. Blackwell, B.: Psychotropic drugs in use today. The role of diazepam in medical practice. Journal of the American Medical Association 225: 1637–1641 (1973).PubMedGoogle Scholar
  10. Boethius, G: Prescription of Drugs 1970–75 in the County of Jamtland, Sweden. Epidemiological and Clinical Pharmacological Aspects (Huddinge University Hospital, Stockholm 1977).Google Scholar
  11. Boethius, G.: Personal communication, presented at WHO Drug Utilization Research Group, Annual Meeting, Prague, August 23–25 (1979).Google Scholar
  12. Bond, A.J.; Hailly, D.M. and Lader, M.H.: Plasma concentrations of benzodiazepines. British Journal of Clinical Pharmacology 4: 51–56 (1977).PubMedGoogle Scholar
  13. Bond, A.J. and Lader, M.H.: Residual effects of hypnotics. Psychopharmacologia 25: 117–132 (1972).PubMedGoogle Scholar
  14. Bond, A.J. and Lader, M.H.: The residual effects of flurazepam. Psychopharmacologia 32: 223–235 (1973).PubMedGoogle Scholar
  15. Bond, A.J. and Lader, M.H.: Residual effects of flunitrazepam. British Journal of Clinical Pharmacology 2: 143–150 (1975).PubMedGoogle Scholar
  16. Borland, R.G and Nicholson, A.N.: Comparison of the residual effects of two benzodiazepines (nitrazepam and flurazepam hydrochloride) and pentobarbitone sodium on human performance. British Journal of Clinical Pharmacology 2: 9–17 (1975).PubMedGoogle Scholar
  17. Borland, R.G. and Nicholson, A.N.: Residual effects of potassium clorazepate, a precursor of nordiazepam. British Journal of Clinical Pharmacology 4: 86–89 (1977).PubMedGoogle Scholar
  18. Boston Collaborative Drug Surveillance Program: Clinical depression of the central nervous system due to diazepam and chlordiazepoxide in relation to cigarette smoking and age. New England Journal of Medicine 288: 277–280 (1973).Google Scholar
  19. Braestrup, C. and Squires, R.F.: Brain specific benzodiazepine receptors. British Journal of Psychiatry 133: 249–260 (1978).PubMedGoogle Scholar
  20. Brandt, R.: Passage of diazepam and desmethyldiazepam into breast milk. Arzneimittel-Forschung 26: 454–457 (1976).PubMedGoogle Scholar
  21. Brophy, J.J.: Suicide attempts with psychotherapeutic drugs. Archives of General Psychiatry 17: 652–657 (1967).PubMedGoogle Scholar
  22. Browne, T.R. and Penry, J.K.: Benzodiazepines in the treatment for epilepsy. A review. Epilepsia 14: 277–310 (1973).PubMedGoogle Scholar
  23. Castledon, C.M.; George, C.F.; Mercer, D. and Hallett, C: Increased sensitivity to nitrazepam in old age. British Medical Journal 1: 10–12 (1977).Google Scholar
  24. Clarke, C.H. and Nicholson, A.N.: Immediate and residual effects in man of the metabolites of diazepam. British Journal of Clinical Pharmacology 6: 325–331 (1978).PubMedGoogle Scholar
  25. Coates, T.J. and Thoresen, C.E.: What to use instead of sleeping pills. Journal of the American Medical Association 240: 2311–2312 (1978).PubMedGoogle Scholar
  26. Cole, A.P. and Hailey, D.M.: Diazepam and active metabolite in breast milk and their transfer to the neonate. Archives of Disease in Childhood 50: 741–742 (1975).PubMedGoogle Scholar
  27. Costa, E.; Guidotti, A. and Toffano, G.: Molecular mechanisms mediating the action of diazepam on GABA receptors. British Journal of Psychiatry 133: 239–248 (1978).PubMedGoogle Scholar
  28. Curry, S.H.: Concentration-effect relationship with major and minor tranquillizers. Clinical Pharmacology and Therapeutics 16: 192–197 (1974).PubMedGoogle Scholar
  29. Dal Bo, L.; Marcucci, F.; Perbellini, D.; Castellani, A.; Fresia, P. and Mussini, E.: Plasma levels of chlordesmethyldiazepam in humans. Submitted to Biopharmaceutics and Drug Disposition (1979).Google Scholar
  30. Dasberg, H.H.; van der Klijn, E.; Guelen, P.J.R. and van Praag, H.M.: Plasma concentrations of diazepam and its metabolite N-desmethyldiazepam in relation to anxiolytic effect. Clinical Pharmacology and Therapeutics 15: 473–483 (1974).PubMedGoogle Scholar
  31. Davis, J.M.; Bartlett, E. and Termini, B.A.: Overdosage of psychotropic drugs: A review. I. Major and minor tranquillizers. Diseases of the Nervous System 29: 157–164 (1968).PubMedGoogle Scholar
  32. De Bard, M.L.: Diazepam withdrawal syndrome: A case with psychosis, seizure and coma. American Journal of Psychiatry 136: 104–105 (1979).PubMedGoogle Scholar
  33. Dundee, J.M.; Johnston, H.M.L.; Lilbura, J.K.; Nair, S.G. and Scott, M.G.: A placebo-controlled comparison of the sedative properties of three benzodiazepines, lorazepam, flunitrazepam and fosazepam. British Journal of Clinical Pharmacology 4: 706–708 (1977).Google Scholar
  34. Editorial: Benzodiazepines — Too many similar compounds? Drug and Therapeutics Bulletin 12: 5–6 (1974).Google Scholar
  35. Editorial: Physical dependence on benzodiazepines? Drug and Therapeutics Bulletin 15: 85–86 (1977).Google Scholar
  36. Editorial: Therapeutic differences between benzodiazepines. Drug and Therapeutics Bulletin 16: 46–48 (1978a).Google Scholar
  37. Editorial: Temazepam for insomnia? Drug and Therapeutics Bulletin 16: 21–22 (1978b).Google Scholar
  38. Editorial: Febrile convulsions and their management. Drug and Therapeutics Bulletin 16: 97–99 (1978c).Google Scholar
  39. Editorial: Diazepam and lorazepam in anaesthesia. Drug and Therapeutics Bulletin 17: 19–20 (1979a).Google Scholar
  40. Editorial: Benzodiazepine withdrawal. Lancet I: 196 (1979b).Google Scholar
  41. Farah, F.; Taylor, W.; Rawlins, M.D. and James, O.: Hepatic drug acetylation and oxidation: Effects of aging in man. British Medical Journal 2: 155–156 (1977).PubMedGoogle Scholar
  42. Fuccella, L.M.; Bolcioni, G.; Tamassia, V.; Ferrario, L. and Tognoni, G.: Human pharmacokinetics and bioavailability of temazepam administered in soft gelatin capsules. European Journal of Clinical Pharmacology 12: 383–386 (1977).PubMedGoogle Scholar
  43. Garattini, S.; Marcucci, F.; Morselli, P.L. and Mussini, E.: The significance of measuring blood levels of benzodiazepines; in Davies and Prichard (Eds) Biological Effects of Drugs in Relation to their Plasma Concentrations, pp.211–225 (MacMillan, London 1973).Google Scholar
  44. Garattini, S.; Marcucci, F. and Mussini, E.: The metabolism and pharmacokinetics of selected benzodiazepines; in Usdin and Forrest (Eds) Psychotherapeutic Drugs — Part III, Applications, pp. 1039–1087 (M. Dekker, New York 1977).Google Scholar
  45. Ghoneim, M.M. and Korttila, K.: Pharmacokinetics of intravenous anaesthetics: implications for clinical use. Clinical Pharmacokinetics 2: 344–372 (1977).PubMedGoogle Scholar
  46. Gillberg, C.: Diazepam at the end of pregnancy grave risks to the neonate. Lakartidningen 74: 2587–2588 (1977).PubMedGoogle Scholar
  47. Gittelman-Klein, R.: Psychopharmacological treatment of anxiety disorders, mood disorders, and Tourette’s disorder in children; in Lipton; DiMascio and Killam (Eds) Psychopharmacology: A Generation of Progress, pp. 1471–1480 (Raven Press, New York 1978).Google Scholar
  48. Goldberg, H.L. and DiMascio, A.: Psychotropic drugs in pregnancy; in Lipton; DiMascio and Killam (Eds) Psychopharmacology: A Generation of Progress, pp.1047–1055 (Raven Press, New York 1978).Google Scholar
  49. Goldstein, B.J.; Brauzer, B.; Steinbook, R.M. and Jacobson, A.F.: Psychotropic drug treatment of mixed anxiety and depression in nonpsychiatric office patients: Expected and unexpected findings — comparing doxepin, chlordiazepoxide and placebo. Southern Medical Journal 66: 892–897 (1973).PubMedGoogle Scholar
  50. Gorbach, A.C.: Diazepam for eclampsia. American Journal of Obstetrics and Gynecology 102: 611–612 (1968).PubMedGoogle Scholar
  51. Gottschalk, L.A.: Pharmacokinetics of the minor tranquilizers and clinical response; in Lipton; DiMascio and Killam (Eds) Psychopharmacology: A Generation of Progress, pp.975–985 (Raven Press, New York 1978).Google Scholar
  52. Graham, P.: Management in child psychiatry: Recent trends. British Journal of Psychiatry 129: 97–108 (1976).PubMedGoogle Scholar
  53. Greenblatt, D.J. and Allen, M.D.: Toxicity of nitrazepam in the elderly: A report from the Boston Collaborative Drug Surveillance Program. British Journal of Clinical Pharmacology 5: 407–413 (1978).PubMedGoogle Scholar
  54. Greenblatt, D.J.; Allen, M.D.; Noel, B.J. and Shader, R.I.: Acute overdosage with benzodiazepine derivatives. Clinical Pharmacology and Therapeutics 21: 497–514 (1977b).PubMedGoogle Scholar
  55. Greenblatt, D.J.; Allen, M.D. and Shader, R.I.: Toxicity of highdose flurazepam in the elderly. Clinical Pharmacology and Therapeutics 21: 355–361 (1977a).PubMedGoogle Scholar
  56. Greenblatt, D.J. and Koch-Weser, J.: Clinical toxicity of chlordiazepoxide and diazepam in relation to serum albumin concentration: A report from the Boston Collaborative Drug Surveillance Program. European Journal of Clinical Pharmacology 7: 259–262 (1974).PubMedGoogle Scholar
  57. Greenblatt, D.J.; Schillings, R.T.; Kyriakopoulos, A.A.; Shader, R.I.; Sisenwine, S.F.; Knowles, J.A. and Ruelius, H.W.: Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral l4C-lorazepam. Clinical Pharmacology and Therapeutics 20: 329–341 (1976).PubMedGoogle Scholar
  58. Greenblatt, D.J. and Shader, R.I.: Benzodiazepines in Clinical Practice (Raven Press, New York 1974).Google Scholar
  59. Greenblatt, D.J. and Shader, R.I.: Prazepam and lorazepam, two new benzodiazepines. New England Journal of Medicine 299: 1342–1344 (1978a).PubMedGoogle Scholar
  60. Greenblatt, D.J. and Shader, R.I.: Dependence, tolerance, and addiction to benzodiazepine: Clinical and pharmacokinetic considerations. Drug Metabolism Review 8: 13–28 (1978b).Google Scholar
  61. Greenblatt, D.J. and Shader, R.I.: Pharmacotherapy of anxiety with benzodiazepines and β-adrenergic blockers; in Lipton; DiMascio and Killam (Eds) Psychopharmacology: A Generation of Progress, pp. 1381–1390 (Raven Press, New York 1978c).Google Scholar
  62. Greenblatt, D.J. and Shader, R.I.: Caution on use of benzodiazepines in the elderly. New England Journal of Medicine 300: 1054–1055 (1979).Google Scholar
  63. Greenblatt, D.J.; Shader, R.I. and Koch-Weser, J.: Flurazepam hydrochloride. Clinical Pharmacology and Therapeutics 17: 1–14 (1975a).PubMedGoogle Scholar
  64. Greenblatt, D.J.; Shader, R.I. and Koch-Weser, J.: Pharmacokinetics in clinical medicine: Oxazepam versus other benzodiazepines. Diseases of the Nervous System 36: 6–13 (1975b).PubMedGoogle Scholar
  65. Greenblatt, D.J.; Shader, R.I. and Koch-Weser, J.: Psychotropic drug use in the Boston area. A report from the Boston Collaborative Drug Surveillance Program. Archives of General Psychiatry 32: 518–521 (1975c).PubMedGoogle Scholar
  66. Greenblatt, D.J. and Shader, R.J.: Treatment of the alcohol withdrawal syndrome; in Shader (Ed) Manual of Psychiatric Therapeutics, pp.211–235 (Little Brown, Boston, Mass. 1975d).Google Scholar
  67. Greenblatt, D.J.; Shader, R.I.; MacLeod, S.M. and Sellers, E.M.: Clinical pharmacokinetics of chlordiazepoxide. Clinical Pharmacokinetics 3: 381–394 (1978a).PubMedGoogle Scholar
  68. Greenblatt, D.J.; Woo, E.; Allen, M.D.; Orsulak, P.J. and Shader, R.I.: Rapid recovery from massive diazepam overdose. J. Amer. Med. Ass. 240: 1872–1874 (1978b).Google Scholar
  69. Griffiths, K.: Who needs the pills? Trends in tranquilliser prescribing in Northern Ireland, presented at WHO Drug Utilization Research Group, Annual Meeting, Prague, August 23–25, 1979.Google Scholar
  70. Grimsson, A.; Idanpaan-Heikkila, J.; Lunde, P.K.M.; Olafsson, O. and Westerholm, B.: The utilization of psychotropic drugs in Finland, Iceland, Norway and Sweden; in Bergman; Grimsson; Wahba and Westerholm (Eds) Studies in Drug Utilization (WHO Regional Publications Eur. Series, No. 8, Copenhagen 1979).Google Scholar
  71. Haefely, W.E.: Central actions of benzodiazepines: General introduction. British Journal of Psychiatry 133: 231–238 (1978).PubMedGoogle Scholar
  72. Hart, J.; Hill, H.M.; Bye, C.E.; Wilkinson, R.T. and Peck, A.W.: The effects of low doses of amylobarbitone sodium and diazepam on human performance. British Journal of Clinical Pharmacology 3: 289–298 (1976).PubMedGoogle Scholar
  73. Hartz, S.C.; Heinonen, O.P.; Shapiro, S.; Siskind, V. and Slone, D.: Antenatal exposure to meprobamate and chlordiazepoxide in relation to malformations, mental development, and childhood mortality. New England Journal of Medicine 292: 726–728 (1975).PubMedGoogle Scholar
  74. Haskell, D.S.; Gambill, J.D.; Gardos, G; McNair, D.M. and Fisher, S.: Doxepin or diazepam for anxious and anxious-depressed outpatients? Journal of Clinical Psychiatry 39: 135–139 (1978).PubMedGoogle Scholar
  75. Hollister, L.E.: Withdrawal from benzodiazepines therapy. Journal of the American Medical Association 237: 1432 (1977).PubMedGoogle Scholar
  76. Hollister, L.E.: Antianxiety drugs; Clinical Pharmacology of Psychotherapeutic Drugs, pp. 12–49 (Churchill Livingstone, New York 1978).Google Scholar
  77. Jick, H.: Adverse drug effects in relation to renal function. American Journal of Medicine 62: 514–517 (1977).PubMedGoogle Scholar
  78. Kales, A.; Scharf, M.B.; Kales, J.D. and Soldatos, C.R.: Rebound insomnia. A potential hazard following withdrawal of certain benzodiazepines. Journal of the American Medical Association 241: 1692–1695 (1979).PubMedGoogle Scholar
  79. Kangas, L.; Iisalo, E.; Kanto, J.; Lehtinen, V.; Pynnonen, S.; Ruikka, I.; Salminen, J.; Sillanpaa, M. and Syvalahti, E.: Human pharmacokinetics of nitrazepam: Effect of age and diseases. European Journal of Clinical Pharmacology 15: 163–170 (1979a).PubMedGoogle Scholar
  80. Kangas, L.; Kanto, J.; Lehtinen, V. and Salminen, J.: Long-term nitrazepam treatment in psychiatric out-patients with insomnia. Psychopharmacology 63: 63–66 (1979b).PubMedGoogle Scholar
  81. Kanto, J.: Benzodiazepines in pregnancy. Clinical Pharmacokinetics. In press (1979).Google Scholar
  82. Karim, A.K.M.B. and Evans, D.A.P.: Polymorphic acetylation of nitrazepam. Journal of Medical Genetics 13: 17–19 (1976).PubMedGoogle Scholar
  83. Keeler, M.H. and McCurdy, R.L.: Medical practice without antianxiety drugs. American Journal of Psychiatry 132: 654–655 (1975).PubMedGoogle Scholar
  84. Kesson, C.M.; Gray, J.M.B. and Lawson, D.H.: Benzodiazepine drugs in general medical patients. British Medical Journal 1: 680–682 (1976).PubMedGoogle Scholar
  85. Klotz, U.; Avant, G.R.; Hoyumpa, A.; Schenker, S. and Wilkinson, G.R.: The effects of age and liver disease on the disposition and elimination of diazepam in adult man. Journal of Clinical Investigation 55: 347–359 (1975).PubMedGoogle Scholar
  86. Klotz, U. and Muller-Seydlitz, P.: Altered elimination of desmethyldiazepam in the elderly. British Journal of Clinical Pharmacology 7: 119–120 (1979).PubMedGoogle Scholar
  87. Kraus, J.W.; Desmond, P.V.; Marshall, J.P.; Johnson, R.F.; Schenker, S. and Wilkinson, G.R.: Effects of aging and liver disease on disposition of lorazepam. Clinical Pharmacology Therapeutics 24: 411–419 (1978).Google Scholar
  88. Kyriakopoulos, A.A.; Greenblatt, D.J. and Shader, R.I.: Clinical pharmacokinetics of lorazepam: A review. Journal of Clinical Psychiatry 39(10): 16–23 (1978).PubMedGoogle Scholar
  89. Lader, M.: Antianxiety drugs: Clinical pharmacology and therapeutic use. Drugs 12: 362–373 (1976).PubMedGoogle Scholar
  90. Lader, M.: Benzodiazepines: The opium of the masses? Neuroscience 3: 159–165 (1978).PubMedGoogle Scholar
  91. Ladinsky, H.; Consolo, S.; Bellantuono, C. and Garattini, S.: Interaction of benzodiazepines with non and putative neurotransmitters in the brain; in Handbook of Biological Psychiatry (M. Dekker, New York, in press 1979).Google Scholar
  92. Lasagna, L.: The role of benzodiazepines in nonpsychiatric medical practice. American Journal of Psychiatry 134: 656–658 (1977).PubMedGoogle Scholar
  93. Linnoila, M. and Mattila, M.J.: Drug interaction on psychomotor skills related to driving: Diazepam and alcohol. European Journal of Clinical Pharmacology 5: 186–194 (1973).Google Scholar
  94. Linnoila, M.; Otterstromn S. and Anttila, M.: Serum chlordiazepoxide, diazepam and thioridazine concentrations after the simultaneous ingestion of alcohol and placebo drink. Annals of Clinical Research 6: 4–6 (1974b).PubMedGoogle Scholar
  95. Linnoila, M.; Saario, I. and Maki, M.: Effect of treatment with diazepam or lithium and alcohol on psychomotor skills related to driving. European Journal of Clinical Pharmacology 7: 337–342 (1974a).PubMedGoogle Scholar
  96. MacLeod, S.M.; Giles, H.G.; Bengert, B.; Liu, F.F. and Sellers, E.M.: Age- and gender-related differences in diazepam pharmacokinetics. Journal of Clinical Pharmacology 19: 15–19 (1979).PubMedGoogle Scholar
  97. MacLeod, S.M.; Giles, H.G.; Patzalek, G.; Thiessen, J.J. and Sellers, E.M.: Diazepam actions and plasma concentrations following ethanol ingestion. European Journal of Clinical Pharmacology 11: 345–349 (1977).PubMedGoogle Scholar
  98. Magnus, R.V.: A placebo controlled trial of Viloxazine with or without tranquillizers in depressive illness. Journal of International Medical Research 3: 207–213 (1975).PubMedGoogle Scholar
  99. Malpas, A.; Rowan, A.J.; Joyce, C.R.B. and Scott, D.F.: Persistent behavioural and electroencephalographic changes after single doses of nitrazepam and amylobarbitone sodium. British Medical Journal 2: 762–764 (1970).PubMedGoogle Scholar
  100. Mandelli, M.; Morselli, P.L.; Nordio, S.; Pardi, G.; Principi, N.; Sereni, F. and Tognoni, G.: Placental transfer of diazepam and its disposition in the newborn. Clinical Pharmacology and Therapeutics 17: 564–572 (1975).PubMedGoogle Scholar
  101. Mandelli, M.; Tognoni, G. and Garattini, S.: Clinical pharmacokinetics of diazepam. Clinical Pharmacokinetics 3: 72–91 (1978).PubMedGoogle Scholar
  102. Marks, J.: The Benzodiazepines: Use, Overuse, Misuse, Abuse. (MTP Press, London 1978).Google Scholar
  103. Mazzi, E.: Possible neonatal diazepam withdrawal: A case report. American Journal of Obstetrics and Gynecology 129: 586–587 (1977).PubMedGoogle Scholar
  104. Medical Letter on Drugs and Therapeutics, 19: 49–50 (1977): Choice of benzodiazepine for treatment of anxiety or insomnia.Google Scholar
  105. Mendels, J.: Depression: The distinction between syndrome and symptom. British Journal of Psychiatry 114: 1549d1554 (1968).Google Scholar
  106. Milkovich, L. and van den Berg, B.J.: Effects of prenatal meprobamate and chlordiazepoxide hydrochloride on human embryonic and fetal development. New England Journal of Medicine 291: 1268–1271 (1974).PubMedGoogle Scholar
  107. Mindham, R.H.S.: Hypnotics and sedatives; in Dukes (Ed.) Meyler’s Side Effects of Drugs, vol. 8, pp.64–83 (Excerpta Medica, Amsterdam 1975).Google Scholar
  108. Mohler, H. and Okada, T.: The benzodiazepine receptor in normal and pathological human brain. British Journal of Psychiatry 133: 261–268 (1978).PubMedGoogle Scholar
  109. Morland, J.; Setekleiv, J.; Haffner, J.F.W.; Stromsaethern C.E.; Danielsen, A. and Holst Wethe, G.: Combined effects of diazepam and ethanol on mental and psychomotor functions. Acta Pharmacologica et Toxicologica 34: 5–15 (1974).PubMedGoogle Scholar
  110. Morselli, P.L.: Pediatric clinical pharmacology routine monitoring or clinical trials? in Gouveia; Tognoni and van der Kleijn (Eds) Clinical Pharmacy and Clinical Pharmacology, pp.277–287 (North Holland, Amsterdam 1976).Google Scholar
  111. Morselli, P.L.; Principi, N.; Tognoni, G.; Raeli, E.; Belvedere, G.; Standen, S.M. and Sereni, F.: Diazepam elimination in premature and full term infants, and children. Journal of Perinatal Medicine 1: 133–141 (1973).PubMedGoogle Scholar
  112. Nicholson, A.N. and Stone, B.M.: Hypnotic activity of 3-hydroxy, N-desmethyldiazepam (oxazepam). British Journal of Clinical Pharmacology 5: 469–472 (1978).PubMedGoogle Scholar
  113. Nisbet, R.; Boulas, S.H. and Kantor, H.I.: Diazepam (Valium) during labor. Obstetrics and Gynecology 29. 726–729 (1967).PubMedGoogle Scholar
  114. Ochs, H.R.; Greenblatt, D.J.; Allen, M.D.; Harmatz, J.S.; Shader, R.I. and Bodem, G.: Effect of age and Billroth gastrectomy on absorption of desmethyldiazepam from clorazepate. Clinical Pharmacology and Therapeutics 26: 449–456 (1979).PubMedGoogle Scholar
  115. Oswald, I.: The why and how of hypnotic drugs. British Medical Journal 1: 1167–1168 (1979).PubMedGoogle Scholar
  116. Patrick, M.J.; Tilstone, W.J. and Reavey, P.: Diazepam and breastfeeding. Lancet I: 542–543 (1972).Google Scholar
  117. Pearson, I.B.: Hypnotics and sedatives; in Dukes (Ed) Side Effects of Drugs, Annual I, pp.21–29 (Excerpta Medica, Amsterdam 1977).Google Scholar
  118. Penry, J.K. and Newmark, M.E.: The use of antiepileptic drugs. Annals of Internal Medicine 90: 207–218 (1979).PubMedGoogle Scholar
  119. Pinder, R.M.; Brogden, R.N.; Speight, T.M. and Avery G.S.: Clonazepam: A review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs 12: 321–361 (1976).PubMedGoogle Scholar
  120. Raihle, J.A. and Papendick, V.E.: Clorazepate dipotassium; in Florey (Ed) Analytical Profiles of Drug Substances, vol. 4, pp. 91–112 (Academic Press, New York 1975).Google Scholar
  121. Randall, L.O. and Kappell, B.: Pharmacological activity of some benzodiazepines and their metabolites; in Garattini, Mussini and Randall (Eds) The Benzodiazepines, pp.27–51 (Raven Press, New York 1973).Google Scholar
  122. Raskin, A.; Schulterbrandt, J.G.; Reatig, N.; Chase, C. and McKeon, J.J.: Differential response to chlorpromazine, im-ipramine, and placebo. Archives of General Psychiatry 23: 164–173 (1970).PubMedGoogle Scholar
  123. Reidenberg, M.M.; Levy, M.; Warner, H.; Coutinho, C.B.; Schwartz, M.A.; Yu, G. and Cheripko, J.: Relationship between diazepam dose, plasma level, age, and central nervous system depression. Clinical Pharmacology and Therapeutics 23: 371–374 (1978).PubMedGoogle Scholar
  124. Rementeria, J.L. and Bhatt, K.: Withdrawal symptoms in neonates from intrauterine exposure to diazepam. Journal of Pediatrics 90: 123–126 (1977).PubMedGoogle Scholar
  125. Rey, E.; d’Athis, Ph.; Giraux, P.; de Lauture, D.; Turquais, J.M.; Chavinie, J. and Olive, G: Pharmacokinetics of clorazepate in pregnant and non-pregnant women. European Journal of Clinical Pharmacology 15: 175–180 (1979).PubMedGoogle Scholar
  126. Rickeis, K.; Gordon, P.E.; Jenkins, B.W.; Perloff, M; Sachs, T. and Stepansky, W.: Drug treatment in depressive illness. (Amitriptyline and chlordiazepoxide in two neurotic populations). Diseases of the Nervous System 31: 30–42 (1970).Google Scholar
  127. Rieder, J. and Wendt, G: Pharmacokinetics and metabolism of the hypnotic nitrazepam; in Garattini, Mussini and Randall (Eds) The Benzodiazepines, pp.99–127 (Raven Press, New York 1973).Google Scholar
  128. Roberts, R.K.; Wilkinson, G.R.; Branch, R.A. and Schenker, S.: Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (Librium). Gastroenterology 75: 479–485 (1978).PubMedGoogle Scholar
  129. Rupp, W.; Badian, M.; Christ, O.; Hajdu, P.; Kulkarni, R.D.; Taeuber, K.; Uihlein, M.; Bender, R. and Vanderbeke, O.: Pharmacokinetics of single and multiple doses of clobazam in humans. British Journal of Clinical Pharmacology 7: 51S–57S (1979).PubMedGoogle Scholar
  130. Russell, G.F.M.; Niaz Uniaza; Wakeling, A. and Slade, P.D.: Comparative double-blind trial of mianserin hydrochloride (Organon GB94) and diazepam in patients with depressive illness. British Journal of Clinical Pharmacology 5: 57S–65S (1978).PubMedGoogle Scholar
  131. Safra, M.J. and Oakley, G.P. Jr.: Association between cleft lip with or without cleft palate and prenatal exposure to diazepam. Lancet II: 478–480 (1975).Google Scholar
  132. Salkind, M.R. and Silverstone, T.: A clinical and psychometric evaluation of flurazepam. British Journal of Clinical Pharmacology 2: 223–226 (1975).PubMedGoogle Scholar
  133. Schatzberg, A.F. and Cole, J.O.: Benzodiazepines in depressive disorders. Archives of General Psychiatry 35: 1359–1365 (1978).PubMedGoogle Scholar
  134. Schmidt, R.T.; Stahl, S.M. and Spehlmann, R.: A pharmacologic study of the stiff-man syndrome. Correlation of clinical symptoms with urinary 3-methoxy-4-hydroxy-phenyl glycol excretion. Neurology 25: 622–626 (1975).PubMedGoogle Scholar
  135. Sellers, E.M.: Clinical pharmacology and therapeutics of benzodiazepines. Clinical Medical Association Journal 118: 1533–1538 (1978).Google Scholar
  136. Sellers, E.M. and Kalant, H.: Pharmacotherapy of acute and chronic alcoholism and alcohol withdrawal syndrome; in Clark and del Giudice (Eds), Principles of Psychopharmacology, 2nd. ed., pp.721–740 (Academic Press, New York 1978).Google Scholar
  137. Sellers, E.M.; MacLeod, S.M.; Greenblatt, D.J. and Giles, H.G.: Inhibition of chlordiazepoxide biotransformation by disulfiram. Clinical Research 24: 652A (1976).Google Scholar
  138. Sellers, E.M.; MacLeod, S.M.; Greenblatt, D.J. and Giles, H.G.: Influence of disulfiram and disease on benzodiazepines disposition (Abstract). Clinical Pharmacology and Therapeutics 21: 117 (1977).Google Scholar
  139. Seppala, T.; Korttila, K.; Hakkinen, S. and Linnoila, M.: Residual effects and skills related to driving after a single oral administration of diazepam, medazepam and lorazepam. British Journal of Clinical Pharmacology 3: 831–841 (1976).PubMedGoogle Scholar
  140. Seppala, T.; Linnoila, M. and Mattila, M.J.: Drugs, alcohol and driving. Drugs 17: 389–408 (1979).PubMedGoogle Scholar
  141. Shader, R.I.; Georgotas, A.; Greenblatt, D.J.; Harmatz, J.S. and Allen, M.D.: Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminium hydroxide. Clinical Pharmacology and Therapeutics 24: 308–315 (1978).PubMedGoogle Scholar
  142. Shader, R.I.; Greenblatt, D.J.; Harmatz, J.S.; Franke, K. and Koch-Weser, J.: Absorption and disposition of chlordiazepoxide in young and elderly male volunteers. Journal of Clinical Pharmacology 17: 709–718 (1977).PubMedGoogle Scholar
  143. Shapiro, A.K.: The placebo effect; in Clark and del Giudice (Eds), Principles of Psychopharmacology, pp.441–459 (Academic Press, New York 1978).Google Scholar
  144. Shull, H.J.; Wilkinson, G.R.; Johnson, R. and Schenker, S.: Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Annals of Internal Medicine 84: 420–425 (1976).PubMedGoogle Scholar
  145. Skegg, D.C.G.; Richards, S.M. and Doll, R.: Minor tranquillisers and road accidents. British Medical Journal 1: 917–919 (1979).PubMedGoogle Scholar
  146. Solomon, F.; White, C.C.; Parron, D.L. and Mendelson, W.B.: Sleeping pills, insomnia and medical practice. New England Journal of Medicine 300: 803–808 (1979).PubMedGoogle Scholar
  147. Solomon, K. and Hart, R.: Pitfalls and prospects in clinical research on antianxiety drugs: Benzodiazepines and placebo. A research review. Journal of Clinical Psychiatry 39: 823–831 (1978).PubMedGoogle Scholar
  148. Svenson, S.E. and Hamilton, R.G: A critique of overemphasis on side effects with the psychotropic drugs: An analysis of 18,000 chlordiazepoxide-treated cases. Current Therapeutics Research 8: 455–464 (1966).Google Scholar
  149. Tansella, M.; Siciliani, O.; Burti, L.; Schiavon, M.; Zimmermann-Tansella, Ch.; Gerna, M.; Tognoni, G. and Morselli, P.L.: N-Desmethyldiazepam and amylobarbitone sodium as hypnotics in anxious patients. Plasma levels, clinical efficacy and residual effects. Psychopharmacologia 41: 81–85 (1975).PubMedGoogle Scholar
  150. Tansella, M.; Zimmermann-Tansella, Ch.; Ferrario, L.; Preziati, L.; Tognoni, G. and Lader, M.: Plasma concentrations of diazepam, nordiazepam and amylobarbitone after short-term treatment of anxious patients. Pharmakopsychiatrie Neuro-Psychopharmakologie 11: 68–75 (1978).Google Scholar
  151. Thiessen, J.J.; Sellers, E.M.; Denbeigh, P. and Dolman, L.: Plasma protein binding of diazepam and tolbutamide in chronic alcoholics. Journal of Clinical Pharmacology 16: 345–351 (1976).PubMedGoogle Scholar
  152. Tomson, G.; Lunell, N.-O.; Sundwall, A. and Rane, A.: Placental passage of oxazepam and its metabolism in mother and newborn. Clinical Pharmacology and Therapeutics 25: 74–81 (1979).PubMedGoogle Scholar
  153. Uhlenhuth, E.H.; Balter, M.B. and Lipman, R.S.: Minor tranquilizers. Clinical correlates of use in an urban population. Archives of General Psychiatry 35: 650–655 (1978).PubMedGoogle Scholar
  154. Verbeeck, R.; Tjandramaga, T.B.; Verberckmoes, R. and DeSchepper, P.J.: Biotransformation and excretion of lorazepam in patients with chronic renal failure. British Journal of Clinical Pharmacology 3: 1033–1039 (1976).PubMedGoogle Scholar
  155. Vessman, J.; Alexanderson, B.; Sjoqvist, F.; Strindberg, B. and Sundwall, A.: Comparative pharmacokinetics of oxazepam and nortriptyline after single oral doses in man; in Garattini, Mussini and Randall (Eds) The Benzodiazepines, pp. 165–173 (Raven Press, New York 1973).Google Scholar
  156. Vinar, O.; Kamenicova, L.; Plechatova, H. and Stika, L.: Who do general practitioners prescribe benzodiazepine anxiolytics? Act. Nerv. Sup. (Praha) 20: 268–269 (1978).Google Scholar
  157. Volz, M.; Christ, O.; Kellner, H.-M.; Kuch, H.; Fehlhaber, H.-W.; Gantz, D.; Hajdu, P. and Cavagna, F.: Kinetics and metabolism of clobazam in animals and man. British Journal of Clinical Pharmacology 7: 41S–50S (1979).PubMedGoogle Scholar
  158. Wang, R.I.H.; Stockdale, S.L. and Hieb, E.: Hypnotic efficacy of lorazepam and flurazepam. Clinical Pharmacology and Therapeutics 19: 191–195 (1975).Google Scholar
  159. Weinstock, R.; Fisher, S.; Spillane, J.; Ise, C.; Shaw, D. and Torop, P.: Effects of protriptyline and perphenazine in neurotic depressed outpatients. Journal of Clinical Pharmacology 15: 627–630 (1975).PubMedGoogle Scholar
  160. Whitehead, W.E.; Blackwell, B. and Robinson, A.: Why physicians prescribe benzodiazepines in essential hypertension. A phase IV Study. Biological Psychiatry 12: 597–601 (1977).PubMedGoogle Scholar
  161. Whiting, B.; Lawrence, J.R.; Skellern, G.G. and Meier, J.: Effect of acute alcohol intoxication on the metabolism and plasma kinetics of chlordiazepoxide. British Journal of Clinical Pharmacology 7: 95–100 (1979).PubMedGoogle Scholar
  162. WHO Drug Utilization Research Group: Annual Meeting, Prague, August 23–25 (1979).Google Scholar
  163. Wilkinson, G.R.: The effects of liver disease and aging on the disposition of diazepam, chlordiazepoxide, oxazepam and lorazepam in man. Acta Psychiatrica Scandinavica, Supplements 274: 56–74 (1978).Google Scholar
  164. Wilson, J. and Ellis, F.R.: Oral premedication with lorazepam (Ativan): A comparison with heptabarbitone (Medomin) and diazepam (Valium). British Journal of Anaesthesia 45: 738–744 (1973).PubMedGoogle Scholar
  165. Wolf, S.M.: Controversies in the treatment of febrile convulsions. Neurology 29: 287–290 (1979).PubMedGoogle Scholar
  166. Zimmermann-Tansella, Ch.: The effects of benzodiazepines on psychological performance in normal subjects and anxious patients. PHD doctoral thesis, University of London (1979).Google Scholar
  167. Zimmermann-Tansella, Ch.; Tansella, M. and Lader, M.: The effects of chlordesmethyldiazepam on behavioral performance and subjective judgment in normal subjects. Journal of Clinical Pharmacology 16: 481–488 (1976).PubMedGoogle Scholar

Copyright information

© ADIS Press Australasia Pty Ltd 1980

Authors and Affiliations

  • C. Bellantuono
    • 1
  • V. Reggi
    • 1
  • G. Tognoni
    • 1
  • S. Garattini
    • 1
  1. 1.Istituto di Ricerche Farmacologiche ‘Mario Negri’MilanoItaly

Personalised recommendations